Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more
Ideaya Biosciences Inc (IDYA) - Total Assets
Latest total assets as of September 2025: $1.19 Billion USD
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) holds total assets worth $1.19 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ideaya Biosciences Inc - Total Assets Trend (2017–2024)
This chart illustrates how Ideaya Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ideaya Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ideaya Biosciences Inc's total assets of $1.19 Billion consist of 61.4% current assets and 38.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.5% |
| Accounts Receivable | $3.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Ideaya Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ideaya Biosciences Inc's current assets represent 61.4% of total assets in 2024, a decrease from 77.7% in 2017.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 34.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Ideaya Biosciences Inc Competitors by Total Assets
Key competitors of Ideaya Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ideaya Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ideaya Biosciences Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ideaya Biosciences Inc is currently not profitable relative to its asset base.
Ideaya Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.44 | 22.93 | 7.47 |
| Quick Ratio | 12.44 | 22.93 | 7.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $738.15 Million | $ 891.55 Million | $ 249.97 Million |
Ideaya Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Ideaya Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.43 |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | 73.1% |
| Total Assets | $1.12 Billion |
| Market Capitalization | $2.65 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ideaya Biosciences Inc's assets at a significant premium ( 2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ideaya Biosciences Inc's assets grew by 73.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ideaya Biosciences Inc (2017–2024)
The table below shows the annual total assets of Ideaya Biosciences Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.12 Billion | +73.12% |
| 2023-12-31 | $649.32 Million | +67.36% |
| 2022-12-31 | $387.97 Million | +1.74% |
| 2021-12-31 | $381.35 Million | +27.85% |
| 2020-12-31 | $298.27 Million | +163.95% |
| 2019-12-31 | $113.00 Million | +17.05% |
| 2018-12-31 | $96.54 Million | +452.33% |
| 2017-12-31 | $17.48 Million | -- |